Exelixis
EXEL
#1685
Rank
ยฃ8.07 B
Marketcap
ยฃ28.27
Share price
2.24%
Change (1 day)
64.29%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : ยฃ0.94 Billion

According to Exelixis's latest financial reports the company has ยฃ0.94 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31ยฃ0.78 B-27.77%
2022-12-31ยฃ1.08 B-0.49%
2021-12-31ยฃ1.08 B22.79%
2020-12-31ยฃ0.88 B36.2%
2019-12-31ยฃ0.64 B18.99%
2018-12-31ยฃ0.54 B90.37%
2017-12-31ยฃ0.28 B-15.67%
2016-12-31ยฃ0.34 B201.8%
2015-12-31ยฃ0.11 B21.64%
2014-12-31ยฃ92.67 M-36.95%
2013-12-31ยฃ0.14 B-42.26%
2012-12-31ยฃ0.25 B103.67%
2011-12-31ยฃ0.12 B18.61%
2010-12-31ยฃ0.10 B-16.04%
2009-12-31ยฃ0.12 B-29.9%
2008-12-31ยฃ0.17 B30.98%
2007-12-31ยฃ0.13 B49.67%
2006-12-31ยฃ91.32 M5.96%
2005-12-31ยฃ86.19 M6.63%
2004-12-31ยฃ80.83 M-39.01%
2003-12-31ยฃ0.13 B-4.27%
2002-12-31ยฃ0.13 B-11.84%
2001-12-31ยฃ0.15 B108.25%
2000-12-31ยฃ75.41 M1665.95%
1999-12-31ยฃ4.27 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
ยฃ3.41 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ5.78 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ11.58 B 1,127.17%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ6.42 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ7.15 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ16.11 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ7.89 B 736.89%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ22.51 M-97.62%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ61.43 M-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA